Have a feature idea you'd love to see implemented?
Let us know!
BDSX Biodesix Inc
Price (delayed)
$1.2
Market cap
$174.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$205.11M
Biodesix, Inc. operates as a biotechnology company. The Company offers non-small cell lung cancer pretreatment serum tests and laboratory testing. Biodesix provides diagnostic tools and equipment for blood and tissue
Highlights
The company's gross profit has surged by 64% YoY and by 8% QoQ
BDSX's EPS has soared by 57% year-on-year and by 16% since the previous quarter
The equity has declined by 23% since the previous quarter
BDSX's debt is up by 22% YoY
Key stats
What are the main financial stats of BDSX
Market
Valuations
Earnings
Shares outstanding
145.47M
Market cap
$174.56M
Enterprise value
$205.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.25
Price to sales (P/S)
2.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
Revenue
$65.56M
EBIT
-$34.98M
EBITDA
-$29.62M
Free cash flow
-$62.39M
Per share
Balance sheet
Liquidity
EPS
-$0.38
Free cash flow per share
-$0.43
Book value per share
$0.19
Revenue per share
$0.45
TBVPS
$0.56
Total assets
$102.74M
Total liabilities
$74.89M
Debt
$61.96M
Equity
$27.86M
Working capital
$31.05M
Debt to equity
2.22
Current ratio
3.4
Quick ratio
3.04
Net debt/EBITDA
-1.03
Margins
Efficiency
Dividend
EBITDA margin
-45.2%
Gross margin
77.7%
Net margin
-66.8%
Operating margin
-53%
Return on assets
-43.3%
Return on equity
-277.4%
Return on invested capital
-39.4%
Return on capital employed
-39%
Return on sales
-53.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BDSX stock price
How has the Biodesix stock price performed over time
Intraday
0.84%
1 week
-14.29%
1 month
-25%
1 year
-9.09%
YTD
-34.78%
QTD
-32.58%
Financial performance
How have Biodesix's revenue and profit performed over time
Revenue
$65.56M
Gross profit
$50.96M
Operating income
-$34.72M
Net income
-$43.82M
Gross margin
77.7%
Net margin
-66.8%
The company's gross profit has surged by 64% YoY and by 8% QoQ
BDSX's net margin has soared by 54% YoY and by 9% QoQ
The operating margin has surged by 52% year-on-year and by 3.1% since the previous quarter
Biodesix's revenue has increased by 49% YoY and by 8% QoQ
Growth
What is Biodesix's growth rate over time
Valuation
What is Biodesix stock price valuation
P/E
N/A
P/B
6.25
P/S
2.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.13
BDSX's EPS has soared by 57% year-on-year and by 16% since the previous quarter
The equity has declined by 23% since the previous quarter
Biodesix's revenue has increased by 49% YoY and by 8% QoQ
The price to sales (P/S) is 16% lower than the last 4 quarters average of 3.2 and 14% lower than the 5-year quarterly average of 3.1
Efficiency
How efficient is Biodesix business performance
The ROE has soared by 82% YoY and by 47% QoQ
BDSX's ROIC has soared by 64% YoY and by 11% QoQ
BDSX's ROS has soared by 56% year-on-year and by 8% since the previous quarter
BDSX's return on assets is up by 42% year-on-year and by 5% since the previous quarter
Dividends
What is BDSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BDSX.
Financial health
How did Biodesix financials performed over time
The company's total assets is 37% higher than its total liabilities
The company's total assets rose by 18% YoY but it fell by 11% QoQ
The total liabilities has declined by 15% year-on-year and by 6% since the previous quarter
BDSX's debt is 122% higher than its equity
The debt to equity has soared by 106% year-on-year and by 31% since the previous quarter
The equity has declined by 23% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.